Browsing by author "Banerji, Udai"
Now showing items 61-74 of 74
-
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Spicer, J; Basu, B; Montes, A; Banerji, U; Kristeleit, R; et al. (NATURE PORTFOLIO, 2023-07-25)All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose ... -
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
Coleman, N; Michalarea, V; Alken, S; Rihawi, K; Lopez, RP; et al. (SPRINGER, 2018-08-01)BACKGROUND: Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically ... -
SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
Yap, TA; Siu, LL; Calvo, E; Lolkema, MP; LoRusso, PM; et al. (ELSEVIER SCIENCE INC, 2021-02-08) -
Searching for treatments for non-G12C-KRAS mutant cancers.
Guo, C; Banerji, U (SPRINGERNATURE, 2021-08-31)KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRASG12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual ... -
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Smyth, LM; Batist, G; Meric-Bernstam, F; Kabos, P; Spanggaard, I; et al. (NATURE PORTFOLIO, 2021-04-16)Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies ... -
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT).
Pal, A; Stapleton, S; Yap, C; Lai-Kwon, J; Daly, R; et al. (BMJ PUBLISHING GROUP, 2021-09-06)INTRODUCTION: Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures-this is reflected in the increasing length of participant information sheets (PIS). ... -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
O'Carrigan, B; Lim, JSJ; Jalil, A; Harris, SJ; Papadatos-Pastos, D; et al. (2018-10-15)Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation ... -
The kinase polypharmacology landscape of clinical PARP inhibitors.
Antolin, AA; Ameratunga, M; Banerji, U; Clarke, PA; Workman, P; et al. (NATURE PORTFOLIO, 2020-02-17)Polypharmacology plays an important role in defining response and adverse effects of drugs. For some mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically done within the same protein ... -
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Saturno, G; Lopes, F; Niculescu-Duvaz, I; Niculescu-Duvaz, D; Zambon, A; et al. (ELSEVIER, 2021-01-13)BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic ... -
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
McVeigh, TP; Sundar, R; Diamantis, N; Kaye, SB; Banerji, U; et al. (ELSEVIER SCI LTD, 2018-05-01)INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, ... -
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
Stewart, A; Thavasu, P; de Bono, JS; Banerji, U (OXFORD UNIV PRESS, 2015-07-01)BACKGROUND: We aimed to understand the relative contributions of inhibiting MEK and AKT on cell growth to guide combinations of these agents. MATERIALS AND METHODS: A panel of 20 cell lines was exposed to either the MEK ... -
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji, U; van Herpen, CML; Saura, C; Thistlethwaite, F; Lord, S; et al. (ELSEVIER SCIENCE INC, 2019-08-01)BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour ... -
Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification.
Stewart, A; Banerji, U (2017-01)The study of protein phosphorylation is critical for the advancement of our understanding of cellular responses to external and internal stimuli. Phosphorylation, the addition of phosphate groups, most often occurs on ... -
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Basu, B; Krebs, MG; Sundar, R; Wilson, RH; Spicer, J; et al. (OXFORD UNIV PRESS, 2018-07-17)BACKGROUND: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients ...